Latest Period
Q1 2026
Security Snapshot
Eton Pharmaceuticals, Inc. - Common Stock (ETON) Institutional Ownership
CUSIP: 29772L108
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
115
Shares (Excl. Options)
17,784,208
Price
$24.68
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ETON on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 17,784,208
- Total 13F value
- $438,556,434
- Portfolio coverage rank
- 0%
- Share change
- +1,381,690
- Value change
- +$36,598,155
- Number of holders
- 115
- Shares outstanding
- 26,828,643
- SEC-reported price per share
- $30.15
- Insider filing price
- $30.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ETON - Eton Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 29772L108.
- 115 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 104 to 115 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $277,512,848 to $438,556,434.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 115 institutions filings for Q1 2026.
Security key
29772L108
Latest holder period
Q1 2026
13F holders
115
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
ETON full holder history
Eton Pharmaceuticals, Inc. SEC filings
Eton Pharmaceuticals, Inc. company facts
Eton Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29772L108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ETON
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7.7% | $28,407,583 | 1,981,003 | EcoR1 Capital, LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 5.7% | $21,807,587 | 1,530,357 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 115 institutional investors reported holding 17,784,208 shares of Eton Pharmaceuticals, Inc. - Common Stock (ETON). This represents 66% of the company’s total 26,828,643 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
57%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 11% | 2,860,000 | 0% | 9.8% | $70,584,800 |
| EcoR1 Capital, LLC | 8.1% | 2,171,938 | +7% | 2.3% | $53,603,430 |
| BlackRock, Inc. | 6.4% | 1,717,286 | -1.2% | 0% | $42,382,617 |
| Nantahala Capital Management, LLC | 4.4% | 1,175,951 | 0% | 1.8% | $29,022,471 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 994,089 | 0% | 0% | $24,534,117 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 577,666 | +2.2% | 0% | $14,260,695 |
| STATE STREET CORP | 2% | 530,215 | +5.6% | 0% | $13,085,706 |
| National Philanthropic Trust | 1.8% | 492,112 | 0% | 0.13% | $12,145,324 |
| MORGAN STANLEY | 1.8% | 477,957 | -3.2% | 0% | $11,795,980 |
| Westside Investment Management, Inc. | 1.7% | 467,915 | -0.64% | 1.8% | $11,548,309 |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.6% | 439,300 | +1.9% | 0.32% | $10,841,924 |
| THOMPSON SIEGEL & WALMSLEY LLC | 1.5% | 406,089 | -0.6% | 0.18% | $10,022,000 |
| Pillsbury Lake Capital LLC | 1.4% | 364,954 | 4.1% | $9,007,065 | |
| CANNELL CAPITAL LLC | 1.3% | 341,985 | +58% | 5.5% | $8,440,190 |
| BNP PARIBAS FINANCIAL MARKETS | 1.1% | 302,108 | 0% | 0% | $7,456,025 |
| NORTHERN TRUST CORP | 0.89% | 237,832 | +2.6% | 0% | $5,869,693 |
| GOLDMAN SACHS GROUP INC | 0.81% | 217,446 | +11% | 0% | $5,366,567 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.7% | 188,802 | +317% | 0.36% | $4,659,633 |
| Aristides Capital LLC | 0.69% | 186,041 | +15% | 1.5% | $4,591,492 |
| Panoramic Capital, LLC | 0.69% | 185,000 | 3.2% | $4,565,800 | |
| Lumbard & Kellner, LLC | 0.66% | 175,911 | +0.55% | 1.5% | $4,341,483 |
| Woodline Partners LP | 0.64% | 170,699 | +79% | 0.02% | $4,212,851 |
| JPMORGAN CHASE & CO | 0.63% | 169,876 | -8.4% | 0% | $3,835,800 |
| UBS Group AG | 0.63% | 168,958 | +33% | 0% | $4,169,883 |
| Soleus Capital Management, L.P. | 0.62% | 166,381 | 0.17% | $4,106,283 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q1 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 17,784,208 | $438,556,434 | +$36,598,155 | $24.68 | 115 |
| 2025 Q4 | 16,409,932 | $277,512,848 | -$34,675,068 | $16.91 | 104 |
| 2025 Q3 | 17,672,584 | $384,025,414 | +$22,957,486 | $21.73 | 101 |
| 2025 Q2 | 16,549,306 | $235,826,915 | +$35,134,963 | $14.25 | 85 |
| 2025 Q1 | 14,123,114 | $183,315,077 | +$11,955,184 | $12.98 | 85 |
| 2024 Q4 | 13,135,396 | $174,958,469 | +$42,338,294 | $13.32 | 70 |
| 2024 Q3 | 9,507,414 | $57,043,272 | +$8,311,784 | $6.00 | 47 |
| 2024 Q2 | 8,228,308 | $27,068,977 | +$3,401,849 | $3.29 | 44 |
| 2024 Q1 | 7,182,688 | $26,933,962 | -$87,277 | $3.75 | 43 |
| 2023 Q4 | 7,158,411 | $31,363,548 | +$1,218,504 | $4.38 | 55 |
| 2023 Q3 | 6,899,800 | $28,769,681 | +$3,931,364 | $4.17 | 50 |
| 2023 Q2 | 5,976,427 | $20,857,388 | +$424,606 | $3.49 | 33 |
| 2023 Q1 | 5,838,481 | $22,478,563 | +$148,362 | $3.85 | 34 |
| 2022 Q4 | 5,937,571 | $18,150,958 | -$813,830 | $2.82 | 31 |
| 2022 Q3 | 6,343,985 | $13,321,785 | +$813,651 | $2.10 | 29 |
| 2022 Q2 | 5,916,510 | $17,660,917 | +$786,718 | $2.62 | 28 |
| 2022 Q1 | 5,783,483 | $27,369,526 | +$1,310,432 | $4.36 | 29 |
| 2021 Q4 | 5,731,001 | $24,586,557 | -$1,088,577 | $4.29 | 30 |
| 2021 Q3 | 5,962,287 | $32,572,856 | -$1,717,167 | $5.04 | 35 |
| 2021 Q2 | 3,148,485 | $22,473,059 | -$10,316,735 | $6.16 | 42 |
| 2021 Q1 | 8,785,097 | $67,961,804 | +$530,664 | $7.32 | 48 |
| 2020 Q4 | 8,725,390 | $74,997,463 | +$13,790,621 | $8.13 | 45 |
| 2020 Q3 | 7,034,912 | $59,521,869 | +$2,214,437 | $7.90 | 38 |
| 2020 Q2 | 6,803,798 | $39,802,008 | +$5,744,437 | $5.45 | 40 |
| 2020 Q1 | 5,967,575 | $24,469,000 | +$13,430,167 | $4.10 | 17 |